A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Inclusion Criteria: * Age ≥ 18 (or as required by local regulation). * Histological or cytological confirmation of unresectable or metastatic solid tumor malignancy harboring a KRAS mutation. * No more than 3 prior standard treatments appropriate for tumor type and stage of disease. * ECOG performance status ≤ 1. * Existence of measurable disease (according to Response evaluation criteria in solid tumors \[RECIST v1.1\] criteria). * Subjects with asymptomatic CNS metastases and/or asymptomatic leptomeningeal carcinomatosis are eligible. * Adequate organ function. Exclusion Criteria: * Major surgery within four weeks of the start of treatment. * Previous other cancer requiring treatment within the previous two years. * Clinically significant cardiovascular disease. * Any of the following cardiac criteria: * Mean resting corrected QT interval (QTc) \> 470 msec obtained from three ECGs and any factors that increase the risk of QTc prolongation or arrhythmic events * Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG * Known clinically significant active infections not controlled with systemic treatment (bacterial, fungal, viral including HIV positivity). * Gastrointestinal disease or other malabsorption syndromes that would impact drug absorption. * Subjects being treated with or anticipating the need for treatment with strong CYP3A inhibitors or inducers.